Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600.
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 6/3/2025 | $8.00 | Neutral | Cantor Fitzgerald | |
| 2/7/2025 | Outperform → Mkt Perform | William Blair | ||
| 12/11/2024 | $11.00 | Overweight → Neutral | Analyst | |
| 11/19/2024 | $7.70 | Sector Perform | Scotiabank | |
| 11/12/2024 | $8.00 → $6.00 | Equal Weight → Underweight | Wells Fargo | |
| 10/7/2024 | $10.00 → $7.00 | Overweight → Underweight | Barclays | |
| 6/6/2024 | $16.00 → $10.00 | Overweight → Neutral | Cantor Fitzgerald | |
| 6/6/2024 | $16.00 → $9.00 | Buy → Neutral | DA Davidson |
Cantor Fitzgerald resumed coverage of Sprinklr with a rating of Neutral and set a new price target of $8.00
William Blair downgraded Sprinklr from Outperform to Mkt Perform
Analyst downgraded Sprinklr from Overweight to Neutral and set a new price target of $11.00
4 - Sprinklr, Inc. (0001569345) (Issuer)
4 - Sprinklr, Inc. (0001569345) (Issuer)
4 - Sprinklr, Inc. (0001569345) (Issuer)
Veradigm (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into real‑world evidence generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm's FollowMyHealth patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project‑specific invitations through trusted channels within FollowMyHealt
Sprinklr (NYSE:CXM), the definitive, AI-native platform for Unified Customer Experience Management (Unified-CXM), today announced that the company's fourth quarter and full year fiscal 2026 financial results will be released before market open on March 11, 2026. The company's earnings press release will be made available on the Sprinklr Investor Relations website at investors.sprinklr.com. Sprinklr will host a conference call to discuss its results at 8:30am ET the same day. Interested parties may register for and access the live webcast of the call at the website. To access the call by phone, dial 877-459-3955 (domestic) or / +1 201-689-8588 (international). The conference ID number is 1
Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, February 17, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm invest
8-K - Veradigm Inc. (0001124804) (Filer)
SCHEDULE 13G/A - Veradigm Inc. (0001124804) (Subject)
144 - Sprinklr, Inc. (0001569345) (Subject)
4 - Sprinklr, Inc. (0001569345) (Issuer)
4/A - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
Sprinklr (NYSE:CXM), the definitive, AI-native platform for Unified Customer Experience Management (Unified-CXM), today announced that the company's fourth quarter and full year fiscal 2026 financial results will be released before market open on March 11, 2026. The company's earnings press release will be made available on the Sprinklr Investor Relations website at investors.sprinklr.com. Sprinklr will host a conference call to discuss its results at 8:30am ET the same day. Interested parties may register for and access the live webcast of the call at the website. To access the call by phone, dial 877-459-3955 (domestic) or / +1 201-689-8588 (international). The conference ID number is 1
Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, February 17, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm invest
Q3 Total Revenue of $219.1 million, up 9% year-over-year Q3 Subscription Revenue of $190.3 million, up 5% year-over-year Q3 net cash provided by operating activities of $20.0 million and free cash flow* of $15.5 million RPO down 5% and cRPO up 3% year-over-year 145 $1 million customers Sprinklr (NYSE:CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today reported financial results for its third fiscal quarter ended October 31, 2025. "Our Q3 results reflect continued progress in our transformation to better serve customers and partners. While there's more work ahead, we're encouraged by the improving quality of customer engagements a
Healthcare IT Veteran - former AWS and Cerner senior executive - to lead and accelerate innovation across Veradigm's unique footprint Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today appoints Tehsin Syed, a healthcare technology leader with over two decades of experience, as Chief Product and Technology Officer. Syed most recently served as General Manager, AWS Health AI (Amazon Web Services). Under his leadership, the organization scaled as a growth engine, with net-new products for ambient clinical documentation, genomics, and medical imaging, and interoperability elevated to enterprise grade - capabilities trusted by providers, payers, bioph
Sprinklr (NYSE:CXM), the unified customer experience management (Unified-CXM) platform for modern enterprises, today announced that Anthony Coletta will join Sprinklr as Chief Financial Officer, effective immediately, reporting to Sprinklr President and CEO, Rory Read. In this role, Coletta will oversee all financial operations, including financial planning and analysis, accounting, investor relations, and strategic growth initiatives. "We are thrilled to welcome Anthony to the Sprinklr team," said Rory Read, President and CEO of Sprinklr. "His proven track record in scaling fast-paced businesses, driving financial performance, and strategic growth makes him an ideal leader to guide our f
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Sprinklr, Inc. (0001569345) (Subject)